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Introduction:  This  study  captures  the  perspectives  of  stakeholders  at  multiple  levels  of  the  vaccine  supply
chain  regarding  their  assessment  of challenges  with  storing  vaccines  within  recommended  temperature
ranges  and  their  perceptions  on the  beneﬁts  of  having  vaccines  with  improved  stability,  including  the
potential  short-term  storage  and  transport  of  vaccines  in a controlled-temperature  chain.
Methods:  Semi-structured  interviews  were  undertaken  with  158  immunization  stakeholders  in  six
countries.  Interviewees  included  national  decision-makers  and  advisors  involved  in vaccine  purchasing
decisions,  national  Expanded  Programme  on  Immunization  managers,  and  health  and  logistics  personnel
at  national,  subnational,  and  health  facility  levels.
Results: Challenges  with  both  heat  and  freeze-exposure  of  vaccines  were  recognized  in  all  countries,  with
heat-exposure  being  a  greater  concern.  Conditions  leading  to freeze-exposure  including  ice  build-up  due
to poor  refrigerator  performance  and  improper  icepack  conditioning  were  reported  by 53% and  28% of
participants,  respectively.  Respondents  were  interested  in vaccine  products  with improved  heat/freeze-
stability  characteristics.  The  majority  of  those  involved  in vaccine  purchasing  indicated  they  would  be
willing  to pay  a US$0.05  premium  per  dose  for a freeze-stable  pentavalent  vaccine  (68%)  or  a heat-
stable  rotavirus  vaccine  (59%),  although  most  (53%)  preferred  not  to pay  the  premium  for  a heat-stable
pentavalent  vaccine  if the  increased  stability  required  changing  from  a liquid  to a lyophilized  product.
Most  respondents  (73%)  were  also  interested  in  vaccines  labeled  for short-term  use  in a  controlled-
temperature  chain.  The  majority  (115/158)  recognized  the ﬂexibility  this  would  provide  during  outreach
or should  cold-chain  breaks  occur.  Respondents  were  also  aware  that possible  confusion  might  arise  and
additional  training  would  be  required  if handling  conditions  were  changed  for some,  but not  all  vaccines.
Conclusion:  Participating  immunization  stakeholders  recognized  the  beneﬁts  of  vaccine  products  with
improved  stability  characteristics  and  of  labeling  vaccines  for controlled-temperature  chain  use as  a
means  to  help  address  cold-chain  issues  in their  immunization  programs.
© 2016  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
The challenge of transporting and storing vaccines at refriger-
ted temperatures (2–8 ◦C) is being addressed on many fronts. The
eed to address this challenge has become increasingly important
ecause of the introduction of new and more expensive vaccines
hat are at risk of damage from heat and/or freeze exposure [1–4]
∗ Corresponding author at: PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA
8121, USA. Tel.: +1 206 302 4693; fax: +1 206 285 6619.
E-mail address: dkriste@path.org (D.D. Kristensen).
1 Present address: Bill & Melinda Gates Foundation, PO Box 23350, Seattle, WA
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264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
and that cumulatively may  overwhelm the already insufﬁcient
cold-chain capacities of many countries [5–8].
Efforts to increase the heat and freeze stability of some vac-
cine products have been quite successful [9], and in 2012 the
World Health Organization (WHO) proposed new programmatic-
suitability requirements for vaccines purchased by United Nations
agencies that set mandatory minimum stability standards and sig-
naled a preference for vaccines that are heat- and freeze-stable and
that can be stored for extended periods of time above 8 ◦C [10].
In 2013, MenAfriVac® became the ﬁrst WHO-prequaliﬁed vaccine
labeled for controlled-temperature chain (CTC) use, allowing a sin-
gle excursion of up to four days at 40 ◦C [11,12]. Over the years, a
number of countries have piloted or adopted protocols permitting
several vaccines to be kept at ambient temperatures for a deﬁned
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table 1
Overview of study participants.
Brazil China India Peru Philippines Tanzania Zanzibarb Total
Country information
Economic classiﬁcationa UMIC UMIC LMIC UMIC LMIC LIC LIC
GAVI-eligible (at time of study)d No No Yes No No Yes Yes
Distribution of participants by role (and supply chain level)
Decision-makers and advisors (national) 7 1 7 3 9 3 0 30
EPI  managers (national) 1 0 1 1 1 1 1 6
Health and logistics personnelc
National level 0 0 0 1 2 1 1 5
Region/province level 3 3 3 7 4 6 2 28
Municipal/district level 4 5 6 9 16 6 4 50
Facility level 4 2 7 6 13 4 3 39
Total  number of participants 19 11 24 27 45 21 11 158
a Country classiﬁcation according to World Bank categories: LIC: low-income country; LMIC: lower-middle-income country; UMIC: upper-middle-income country. Source:
http://data.worldbank.org/country.
b Zanzibar is assumed to be treated as part of Tanzania in terms of GAVI-eligibility, although it has a separate EPI Manager and Ministry of Health team.
.gavialliance.org/results/countries-approved-for-support/.
ealth workers.
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Fig. 1. Perceived concerns regarding vaccine temperature exposures reported byc GAVI eligibility is based on support for pentavalent vaccine. Source: http://www
d Health and logistics personnel include cold-chain managers, logisticians, and h
eriod of time to ease logistical challenges and eliminate the need
or icepacks for transport [13–17].
To our knowledge, no study to date has captured stake-
older perspectives at multiple levels of the vaccine supply chain
egarding the need for vaccines with improved stability and their
pinions on how use of vaccines in a CTC might help to mitigate
upply chain challenges. This article summarizes the views of stake-
olders in six countries of varying income classiﬁcations that have
ecently introduced new vaccines into their national immuniza-
ion programs. The results are meant to inform ongoing initiatives
o improve vaccine distribution and storage through enhanced vac-
ine stability.
. Methods
The opinions of 158 immunization stakeholders in Brazil, China,
ndia, Peru, the Philippines, and Tanzania (both mainland and
anzibar) were sought via semi-structured, one-on-one interviews
etween October 2011 and March 2012. Countries were selected to
epresent demographic, geographic, and economic diversity. Inter-
iew sites and participants were chosen in collaboration with the
xpanded Programme on Immunization (EPI) manager (or equiva-
ent) in each country using a sampling methodology inclusive of all
evels of the supply chain and representative of low and high rates
f third dose of diphtheria, tetanus, pertussis (DTP3) combination
accine coverage. A summary of study participants is presented in
able 1.
Three different semi-structured questionnaires were used for
he interviews, tailored to the roles of the interviewees as follows:
1) national decision-makers and advisors involved in vaccine-
urchasing decisions, (2) national EPI managers, and (3) health and
ogistics personnel, including subnational EPI managers, logisti-
ians, physicians, and nurses. The questionnaires were developed in
nglish, translated into local language where necessary, and pilot-
ested. A local immunization expert and a translator, if needed,
ere present at the time of the interview to ensure questions and
esponses were clearly articulated and accurately transcribed.
Survey questions reported on in this article focused on cold-hain challenges, the value of more stable vaccines, and the CTC
oncept.2 Survey responses were translated (if needed), aggre-
ated, and analyzed in Excel.
2 This article deals with a sub-set of the survey questions. Other results will be
resented separately.country.
3. Results
3.1. Perceptions and challenges with vaccine heat and freeze
exposure
To better understand the perceived need for vaccines with heat
and freeze stability, participants were asked whether exposure to
heat or freezing temperatures was of greater or equal concern.
Forty-six percent of all participants (73/158) believed that expo-
sure to heat was  a greater concern, 32% (50/158) believed that heat
and freezing were equal concerns, 15% (24/158) believed freeze-
exposure to be the primary concern, 3% (4/158) reported that they
did not know, and 4% (7/158) did not respond. Fig. 1 details the
responses by country.
When asked speciﬁcally whether exposure of vaccines to freez-
ing temperatures is a problem in their immunization program,
only 35% (55/158) of participants said “yes.” Fig. 2 shows the
breakdown by country. To better understand the likelihood of
exposure to freezing, the following questions were then asked:
“Are icepacks typically taken directly from the freezer and placed
into the vaccine carrier prior to outreach (i.e., without condition-
ing)?” and “Does ice build-up occur inside the refrigerator or do
temperatures fall below 0 ◦C in the refrigerator?” Sixty-four per-
cent (101/158) of respondents said “yes” to one or both of these
questions indicating awareness of conditions that could lead to
freezing.
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Fig. 2. Participants stating that exposure of vaccines to freezing temperatures occurs
in their immunization program.
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price increase of US$0.05 per dose was chosen, which does not indi-
cate actual or predicted price increases. Sixty-eight percent (19/28)
of those who responded stated they would be willing to pay more
3 This represents a hypothetical scenario drafted prior to the establish-
ment of WHO  programmatic criteria for CTC-labeled vaccines. WHO  criteria
states “the vaccine must be able to tolerate ambient temperatures of at
◦Fig. 3. Potential sources of vaccine freeze-exposure reported by country.
Poor refrigerator performance was reported by 53% (84/158) of
articipants and improper icepack conditioning was  reported by
8% (44/158) of participants (Fig. 3).
.2. Reported incidence of vaccine wastage
Thirty-ﬁve percent (56/158) of participants recalled one or more
ncidents over the last few years resulting in the discard of large
uantities of vaccine. Forty-four percent (70/158) believed that no
ncidents had occurred, 2% (3/158) did not know, and 18% (29/158)
id not respond. Among the reasons given for loss of a large quantity
f vaccine, the majority (29/60) was due to expiry, followed by heat
xposure (22/60). Some of the incidents leading to heat exposure
ncluded power outages, equipment failures, transportation delays,
r delivery truck arrival on a holiday or after working hours.
.3. Opinions on use of a controlled-temperature chainParticipants were provided with the following scenario before
eing asked a series of questions about potential use of a CTC for
accines:e 34 (2016) 899–904 901
It might be possible for some vaccines to be labeled as follows:
“Store from +2 ◦C to +8 ◦C. Can be stored up to 37 ◦C for 30 days or
less. Do not freeze.”3
Overall, 73% (115/158) of participants believed there would
be circumstances where it might be helpful to temporarily store
or transport vaccines labeled as above without refrigeration or
ice. Across all countries, 85% (33/39) of participants at the facil-
ity, 74% (37/50) at the municipal/district, 71% (20/28) at the
regional/provincial, and 61% (25/41) at the national level believed
it would be helpful. By country, the proportion of participants who
thought CTC use would be helpful were as follows: mainland Tan-
zania (95%), Philippines (87%), Brazil (79%), India (75%), Zanzibar
(64%), Peru (44%), and China (36%).
All participants were asked to imagine circumstances in their
immunization program where having vaccines labeled for CTC use
could be beneﬁcial. Open-ended responses included: during power
outages or when gas or backup generators are not available (35
responses), at peripheral health facilities without refrigerators (29
responses), to facilitate outreach (22 responses), to provide an addi-
tional assurance of heat stability when means to monitor cold chain
equipment is difﬁcult or unavailable (19 responses), and when ice
is not available or ice in vaccine carriers melts (18 responses). Five
participants mentioned that this strategy should be used only in
a campaign setting and not in routine immunization due to the
potential for confusion.
All participants were asked their opinion on the minimum
length of time for vaccine storage or transport without ice or refrig-
eration that they believed would be useful, and 84% (132/158) gave
their opinion while 26 participants did not know or said no amount
of time would be useful. The responses have been clustered in time
ranges for brevity. Less than 1 day was proposed by 16% (21/132),
1–2 days by 11% (14/132), 3–7 days by 13% (17/132), 8–14 days by
9% (12/132), 15–30 days by 34% (45/132), and over 30 days by the
remaining 17% (23/132) of respondents. The responses from those
suggesting shorter periods (2 weeks or less) of CTC use generally
corresponded to interest in using a CTC when cold-chain breaks
occur or to facilitate outreach or short-term storage at remote facil-
ities lacking access to power. The suggested longer time periods
(greater than 3 months) for CTC use generally reﬂected interest in
routine storage of all vaccines without refrigeration.
Of the 27% (43/158) who did not perceive any beneﬁts from CTC
use for vaccines, 91% (39/43) expressed concern that it would be
too confusing and pose a safety risk if some but not all vaccines
could be used in a CTC. In addition, 28% (12/43) considered that
health workers would not be able to ensure vaccine quality during
CTC use, especially in climates with temperatures exceeding 37 ◦C.
The new WHO  threshold of 40 ◦C might help to mitigate some of
this concern.
3.4. Opinions about tradeoffs between vaccine product cost,
presentation format, and improved stability
National decision-makers, advisors, and EPI managers (n = 36)
were asked three theoretical questions to determine their prefer-
ences with regard to alternative vaccine products. A representativeleast +40 C for a minimum of three days.” Source: World Health Organiza-
tion. Vaccine Management and Logistics: Controlled Temperature Chain. October
9, 2015. Available at: http://www.who.int/immunization/programmes systems/
supply chain/resources/tools/en/index6.html.
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or a liquid pentavalent vaccine that could not be damaged by freez-
ng, with remarks such as “a freeze stable vaccine would be more
ost-effective,” it would “offer greater safety,” it is “worth the price
ecause it will provide more efﬁcacy and protection,” and it “would
e easier to manage vaccines; there would be less need for moni-
oring and training on the shake test.”
Twenty-ﬁve percent (7/28) would prefer to purchase penta-
alent vaccine at the current price, even though it is susceptible
o freeze damage. Participants from Brazil, the Philippines, Tan-
ania, and Zanzibar who chose the current pentavalent vaccine
ommented that there was  not a problem with freezing of vaccines
n their country. A participant from India commented that, “with
he millions of vaccines purchased annually, 1 rupee per dose would
esult in a large increase in price.” Two participants responded
hat they did not know. One participant from the Philippines com-
ented “We  have to yet discuss the pros and cons, estimate the
osts and compare, address operational issues.”
Fifty-nine percent (19/32) of the responding participants would
e willing to pay more for a liquid rotavirus vaccine that is heat
table. Of these, six commented that a more stable vaccine would
acilitate reductions in transport and storage costs and vaccine
astage. A participant from Brazil commented, “This would [be]
n interesting study for ﬁnance to perform a risk-beneﬁt analysis.”
 participant from Tanzania commented, “For all vaccines, I would
lways go for the most stable, because this reduces the risk.”
In contrast, 34% (11/32) would prefer the current rotavirus vac-
ine that is less heat stable at the current price. One participant
ommented that the “cost is not justiﬁable in Peru, as [the country]
oes not have a policy to take vaccines out of the cold chain.” Two
articipants remarked that price is important and 7 days of heat
tability is sufﬁcient. Two participants did not express a preference.
When compared to a lyophilized hepatitis vaccine that is more
eat stable at the same price, 53% (17/32) of respondents would
refer a hepatitis B vaccine that is liquid with the stability of current
roducts. Five participants commented that lyophilized vaccines
hould be avoided when possible, as they take time, can cause con-
usion, and require reconstitution syringes and diluents that are
ften kept outside of the refrigerator until the day of vaccination.
ne participant commented, “The concern is at the lower level –
f they can keep [a vaccine] for one month without a refrigerator,
hat would be worthwhile. But, if the refrigerator is already there,
his does not offset the cost of the time spent to reconstitute, store
iluent, syringe, etc.”
Forty-one percent of those responding (13/32) preferred a hep-
titis B vaccine that is lyophilized and more heat stable, noting
hat a more stable product would “reduce risk,” “reduce cost,” and
reduce wastage.” One participant commented “[we] could keep
he vaccine for a long time for birth-dose delivery.”
. Discussion
While previous studies have assessed vaccine cold chains
18,19], monitored temperatures during vaccine storage and dis-
ribution [20,21], and focused on the use of speciﬁc antigens in a
TC [22–24], our research attempts to offset the paucity of data on
he perceptions of country stakeholders regarding their challenges
n maintaining vaccines in a 2–8 ◦C temperature range and interest
n purchasing and using vaccine products with improved stability.
.1. Heat exposure, heat-stable vaccines, and CTC use of vaccinesIt is important to note that this survey captured the perceived
auses of vaccine loss and not the actual amounts of vaccine lost
ue to expiry or to heat or freeze damage. In this context, discards
ue to expiration ranked ﬁrst, heat exposure ranked second, ande 34 (2016) 899–904
freeze exposure ranked third. The evidence base of actual vaccine
wastage due to heat and freeze exposure remains sparse. Three of
the six countries surveyed in this study (Brazil, China, and Peru)
do not have vaccine vial monitors to help identify when vaccines
have received excessive heat exposure and should be discarded,
or whether they can be retained after cold chain breaks. Interest-
ingly, Brazil and China had the greatest percentage of participants
expressing concerns about vaccine heat exposure, possibly because
vaccines are discarded as a precaution when heat exposures occur.
Additional research would be required to see whether this is the
case.
There are several ways to prevent vaccine wastage from heat
exposure, including improved heat stability to prolong the use-
ful life of vaccines when they are exposed to higher temperatures.
While our sample size of vaccine purchasing decision-makers and
advisors is small (36 national level respondents), the results from
this study indicate that the majority (59%) would be willing to pay
more for a liquid rotavirus vaccine that is more heat stable. How-
ever, a slight majority (53%) would be unwilling to switch to a more
heat-stable hepatitis B vaccine at the same price if the switch meant
moving from a liquid to a lyophilized product. Lyophilized vaccines
require diluent and must be reconstituted before use, resulting in
increased product volumes, logistical concerns, and potential safety
issues.
Vaccines can be labeled for higher temperature storage if vac-
cine manufacturers have conducted sufﬁcient stability testing and
obtained regulatory approval. Efforts continue to assess the pros
and cons of intentionally removing key heat-stable vaccines from
the cold chain at the periphery of health systems to facilitate out-
reach and improve immunization coverage [11,12,23]. Whenever
these vaccines are exposed to ambient temperatures, care must be
taken to ensure that the exposure temperature does not exceed
the limit on the label (e.g., 40 ◦C for not more than 4 days for
MenAfriVac).
The majority of interviewees felt that such use of a CTC for
vaccines would be feasible and beneﬁcial for making longer out-
reach trips and that more heat stable vaccines would provide some
allowable margin for temporary heat excursions during cold-chain
breaks. Twenty-two percent (29/132) thought that the minimum
length of time needed for keeping vaccines in a CTC should be
between 3 days and 2 weeks – an achievable target for many vac-
cines that also would be compliant with new WHO  guidelines [25].
Use of a CTC for vaccines may  offer other advantages that partici-
pants also acknowledged, such as the avoidance of vaccine freezing,
removal of the need to freeze and condition icepacks, and less
weight for transport when ice is not used.
Respondents were aware of the complexity of having different
rules for different vaccines and the accompanying need for addi-
tional training and tools to appropriately implement vaccine CTC
use [12,26]. Further CTC studies are needed to advance the under-
standing of the feasibility, costs, and beneﬁts of intentional removal
of vaccines from cold chains. Ideally, more vaccines will be labeled
for higher temperature storage in the future in accordance with
WHO’s existing recommendation [10].
4.2. Freeze exposure and freeze-stable vaccines
Exposure to freezing temperatures was recognized as a con-
cern in all countries by at least a few participants, though it was
reported to be a lesser cause of vaccine loss than expiry and heat
exposure. However, conditions leading to vaccine freeze exposure
were identiﬁed by the majority of participants, suggesting that
vaccine freezing may  occur, but goes unrecognized. In a review
of cold-chain monitoring studies in developing countries, 35% of
shipments and 22% of storage facilities reported temperatures
below the freezing threshold for vaccines [1] and a more recent
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tudy in India reports even higher incidents of freeze exposure,
specially at peripheral facilities [4]. The fact that freeze exposure
as less frequently identiﬁed as a problem in our study than heat
xposure could be due to the fact that heat exposure is often more
vident (e.g., when power outages occur), may  affect greater quan-
ities of vaccine, and can be signaled with vaccine vial monitors.
reeze exposure is less obvious and likely affects smaller quanti-
ies of vaccine (e.g., placed near ice in vaccine carriers or near cold
pots in refrigerators). Vaccines can therefore freeze and thaw, and
ealth workers may  not visually inspect vaccines for evidence of
reeze damage before use. Although the shake-test can detect vac-
ines that have been frozen [27], it is not often used. Based on
he number of reported incidents of ice build-up in refrigerators
nd improper icepack conditioning, the likelihood of unrecognized
reeze events is high.
Both equipment and vaccine product improvements can help to
ddress the problem of inadvertent vaccine freeze exposure. Better
emperature monitoring, better training, and improved refrigera-
ion and transport containers that prevent freezing are deﬁnitely
eeded. WHO  is working to advance new categories of prequaliﬁed
old-chain equipment with built-in freeze protection [28]; vaccine
arriers are the ﬁrst to meet this criterion. In addition, vaccines
ontaining aluminum adjuvant (one of the main causes of freeze
ensitivity) can be formulated to be freeze-stable using methodol-
gy that has been placed in the public domain [29,30], a feature
or which the majority (68%) of those involved in vaccine purchas-
ng were willing to pay a suggested premium. The addition of the
reeze-stability characteristic would be most cost-effective for vac-
ines that are in development, as it would have negligible impact
n the development cost or price of these vaccines [2,31].
. Limitations
The study only surveyed a small number of individuals in a few
ountries and should not be considered a representative sample.
he ﬁndings presented are designed to illuminate the opinions of
takeholders with a variety of diverse perspectives and priorities.
. Conclusions
Immunization stakeholders in the participating low- and
iddle-income countries expressed interest in the availability and
urchase of vaccine products with improved heat- and freeze-
tability characteristics. Respondents also valued the concept of
eceiving vaccines whose labels reﬂect their ability to withstand
hort-term exposure to high temperatures. They recognized the
eneﬁts of such labeling in terms of improved information about
otential vaccine damage should cold-chain breaks occur as well as
n the possibility of purposefully removing vaccines from refrigera-
ion as long as CTC conditions are maintained. Their concerns about
he issues surrounding changes to vaccine handling conditions for
 subgroup of EPI vaccines highlight the need to carefully consider
urposeful removal of CTC-qualiﬁed vaccines from the cold chain to
nsure that the beneﬁts are maximized and outweigh the potential
isks and additional efforts required.
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